Contact Us: +91 9821590174
  • about us
  • therapy focus
    • Medicinal therapy
    • Nutritional therapy
  • Brand portfolio
    • Medicinal Therapy

      • Tyrosinemia
      • Brunity


    • Nutritional Therapy

      • Phenylketonuria
      • PKU A formula
      • PKU B formula
      • PKU B (concentrate)
      • PKU express15 & 20
      • PKU express15 plus & 20 plus
      • Tyrosinemia
      • TYRo A Formula
      • TYR explore5
      • TYR gel
      • TYRo B Formula
      • TYR cooler15
      • TYR express plus 15 and 20
  • alliances
    • International alliances
    • Domestic alliances
  • patient assitances
    • Tyrosinemia
  • resources
    • News
    • Research and Journal
    • Blogs
    • Others
  • Events
  • contact us

Raising awareness and generating change for 300 million people worldwide living with rare diseases. We are 38 years old growing pharmaceutical conglomerate serving as a reliable partner.

Company
About UsTherapy FocusBrand PortfolioAlliances
Quick Links
Contact UsNewsEventsPrivacy Policy
Contact
+91 98215 90174info@brawnraredisease.in

All Rights Reserved © 2024 Brawn Rare Disease

Designed by Cyberworx

Alkaptonuria ​

Assisting in the fight against Alkaptonuria

Aiding in the battle against Alkaptonuria, our efforts are dedicated to supporting individuals affected by this condition through innovative treatments, research initiatives, and community empowerment, striving to improve outcomes and enhance quality of life.

  • About Disease
  • Medicines/Nutrition
  • Legal Advocacy
  • Diagnosis
  • News

Alkaptonuria is a congenital disorder caused by a deficiency of the enzyme homogentisate-1,2-dioxygenase (HGD), which catalyses the conversion of homogentisic acid (HGA) to maleylacetoacetate. As a consequence, there is an accumulation of HGA and its derivative benzoquinone-acetic acid in the body, which are toxic to several tissues like cartilage. The long-term consequences of AKU are joint problems, cardiac valve abnormalities, kidney stones and sometimes renal insufficiency